Average proportion of days covered (PDC) for individuals with antiplatelet therapy during the 12 months following implantation of a coronary artery drug-eluting stent (DES) or a bare-metal stent (BMS).
-
-
1.5 Measure Type1.7 Electronic Clinical Quality Measure (eCQM)1.8 Level Of Analysis1.9 Care Setting1.20 Testing Data Sources
-
1.14 Numerator
The sum of the days covered by the days’ supply of all antiplatelet prescriptions during the days measured in the denominator
-
1.15 Denominator
The sum of the days measured for all individuals who undergo a coronary artery drug-eluting stent (DES) or bare-metal stent (BMS) placement at any time during the first 12 months of the 24-month measurement period and have at least two prescriptions for antiplatelet therapy during the 12 months following stent placement
-
Exclusions
Individuals with a history of contraindication(s) to antiplatelet therapy are excluded. Contraindications include peptic ulcer disease, intracranial hemorrhage, and gastrointestinal (GI) bleed.
-
Most Recent Endorsement Activity - OLDMeasure Retired and Endorsement Removed Cardiovascular Spring Cycle 2018Initial EndorsementLast UpdatedRemoval Date
-
StewardCenters for Medicare & Medicaid ServicesSteward Organization POC EmailSteward Organization Copyright
Limited proprietary coding is contained in the measure specifications for user convenience. Use of these codes may require permission from the code owner or agreement to a license.
ICD-10 codes are copyright © World Health Organization (WHO), Fourth Edition, 2010.
-
-
-
Risk Adjustment
-
-
-
6.1.2 Current or Planned Use(s)6.1.3 Current Use(s)
-